These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

205 related items for PubMed ID: 29608486

  • 1. Simultaneous Quantification of Adalimumab and Infliximab in Human Plasma by Liquid Chromatography-Tandem Mass Spectrometry.
    Jourdil JF, Némoz B, Gautier-Veyret E, Romero C, Stanke-Labesque F.
    Ther Drug Monit; 2018 Aug; 40(4):417-424. PubMed ID: 29608486
    [Abstract] [Full Text] [Related]

  • 2. Infliximab quantitation in human plasma by liquid chromatography-tandem mass spectrometry: towards a standardization of the methods?
    Jourdil JF, Lebert D, Gautier-Veyret E, Lemaitre F, Bonaz B, Picard G, Tonini J, Stanke-Labesque F.
    Anal Bioanal Chem; 2017 Feb; 409(5):1195-1205. PubMed ID: 27826630
    [Abstract] [Full Text] [Related]

  • 3. Simultaneous Quantification of Free Adalimumab and Infliximab in Human Plasma Using a Target-Based Sample Purification and Liquid Chromatography-Tandem Mass Spectrometry.
    El Amrani M, Bosman SM, Egas AC, Hack CE, Huitema ADR, van Maarseveen EM.
    Ther Drug Monit; 2019 Oct; 41(5):640-647. PubMed ID: 31584927
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Infliximab and adalimumab concentrations and anti-drug antibodies in inflammatory bowel disease control using New Zealand assays.
    Barclay ML, Karim S, Helms ETJ, Keating PE, Hock B, Stamp LK, Schultz M.
    Intern Med J; 2019 Apr; 49(4):513-518. PubMed ID: 30091273
    [Abstract] [Full Text] [Related]

  • 9. Simultaneous quantification of rituximab and eculizumab in human plasma by liquid chromatography-tandem mass spectrometry and comparison with rituximab ELISA kits.
    Truffot A, Jourdil JF, Seitz-Polski B, Malvezzi P, Brglez V, Stanke-Labesque F, Gautier-Veyret E.
    Clin Biochem; 2021 Jan; 87():60-66. PubMed ID: 33096054
    [Abstract] [Full Text] [Related]

  • 10. Quantification of infliximab and adalimumab in human plasma by a liquid chromatography tandem mass spectrometry kit and comparison with two ELISA methods.
    Tron C, Lemaitre F, Bros P, Goulvestre C, Franck B, Mouton N, Bagnos S, Coriat R, Khoudour N, Lebert D, Blanchet B.
    Bioanalysis; 2022 Jun; 14(11):831-844. PubMed ID: 35735172
    [Abstract] [Full Text] [Related]

  • 11. Routinely utilized in-house assays for infliximab, adalimumab and their anti-drug antibody levels.
    Ogrič M, Žigon P, Drobne D, Štabuc B, Sodin-Semrl S, Čučnik S, Praprotnik S.
    Immunol Res; 2018 Dec; 66(6):726-736. PubMed ID: 30569379
    [Abstract] [Full Text] [Related]

  • 12. Optimization of a Quantitative Anti-Drug Antibodies against Infliximab Assay with the Liquid Chromatography-Tandem Mass Spectrometry: A Method Validation Study and Future Perspectives.
    Smeijsters EH, van der Elst KCM, Visch A, Göbel C, Loeff FC, Rispens T, Huitema ADR, van Luin M, El Amrani M.
    Pharmaceutics; 2023 May 12; 15(5):. PubMed ID: 37242719
    [Abstract] [Full Text] [Related]

  • 13. A retrospective comparison of infliximab versus adalimumab as induction and maintenance therapy for Crohn disease.
    Varma P, Paul E, Huang C, Headon B, Sparrow MP.
    Intern Med J; 2016 Jul 12; 46(7):798-804. PubMed ID: 26865349
    [Abstract] [Full Text] [Related]

  • 14. Development of Label-Free Immunoassays as Novel Solutions for the Measurement of Monoclonal Antibody Drugs and Antidrug Antibodies.
    Luo YR, Chakraborty I, Lazar-Molnar E, Wu AHB, Lynch KL.
    Clin Chem; 2020 Oct 01; 66(10):1319-1328. PubMed ID: 32918468
    [Abstract] [Full Text] [Related]

  • 15. Surface plasmon resonance assays for the therapeutic drug monitoring of infliximab indicate clinical relevance of anti-infliximab antibody binding properties.
    Grasmeier MK, Weber S, Treiber M, Thaler MA, Luppa PB.
    Clin Chem Lab Med; 2023 Jun 27; 61(7):1255-1265. PubMed ID: 36753693
    [Abstract] [Full Text] [Related]

  • 16. A Genetic Variation in the Neonatal Fc-Receptor Affects Anti-TNF Drug Concentrations in Inflammatory Bowel Disease.
    Billiet T, Dreesen E, Cleynen I, Wollants WJ, Ferrante M, Van Assche G, Gils A, Vermeire S.
    Am J Gastroenterol; 2016 Oct 27; 111(10):1438-1445. PubMed ID: 27481307
    [Abstract] [Full Text] [Related]

  • 17. Comparison of a new rapid method for determination of serum anti-adalimumab and anti-infliximab antibodies with two established ELISA kits.
    Laserna-Mendieta EJ, Salvador-Martín S, Marín-Jiménez I, Menchén LA, López-Cauce B, López-Fernández LA, Lucendo AJ.
    J Pharm Biomed Anal; 2021 May 10; 198():114003. PubMed ID: 33714800
    [Abstract] [Full Text] [Related]

  • 18. The efficacy and safety of either infliximab or adalimumab in 362 patients with anti-TNF-α naïve Crohn's disease.
    Narula N, Kainz S, Petritsch W, Haas T, Feichtenschlager T, Novacek G, Eser A, Vogelsang H, Reinisch W, Papay P.
    Aliment Pharmacol Ther; 2016 Jul 10; 44(2):170-80. PubMed ID: 27226407
    [Abstract] [Full Text] [Related]

  • 19. Generation of a Highly Specific Monoclonal Anti-Infliximab Antibody for Harmonization of TNF-Coated Infliximab Assays.
    Van Stappen T, Brouwers E, Tops S, Geukens N, Vermeire S, Declerck PJ, Gils A.
    Ther Drug Monit; 2015 Aug 10; 37(4):479-85. PubMed ID: 25525757
    [Abstract] [Full Text] [Related]

  • 20. Anti-TNF Levels in Cord Blood at Birth are Associated with Anti-TNF Type.
    Kanis SL, de Lima-Karagiannis A, van der Ent C, Rizopoulos D, van der Woude CJ.
    J Crohns Colitis; 2018 Jul 30; 12(8):939-947. PubMed ID: 29771301
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.